PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28066430-6	2016	ATV treatment for 7 days increased the frequency of Tregs in mediastinal lymph nodes (MLN) and the interleukin (IL)-10 in lungs.	Atorvastatin	0-3	interleukin 10	Mus musculus	99-118	
28835272-14	2017	Notably, atorvastatin treatment significantly increased the proportion of regulatory T cells (Tregs) in both the peripheral spleen and brain, and at the same time, increased their main effector cytokines IL-10 and TGF-beta1.	Atorvastatin	9-21	interleukin 10	Mus musculus	204-209	
21428710-10	2011	Furthermore, atorvastatin treatment switches Th1 type T-cell response toward/to Th2 (IL-4, IL-10) type response.	Atorvastatin	13-25	interleukin 10	Mus musculus	91-96	
21421071-9	2011	RESULTS: In the protective phase, Atorvastatin inhibited the OVA-induced cellular infiltration of lung bronchi, decreased IL-4 and IL-5 and prevented the increase in IL-10 cytokine levels.	Atorvastatin	34-46	interleukin 10	Mus musculus	166-171	
16984105-3	2006	Atorvastatin increased the level of IL-10 by 41%, while 7-ketocholesterol and 25-hydroxycholesterol inhibited its secretion by 48 and 55%.	Atorvastatin	0-12	interleukin 10	Mus musculus	36-41	
12422218-4	2002	Atorvastatin induced STAT6 phosphorylation and secretion of Th2 cytokines (interleukin (IL)-4, IL-5 and IL-10) and transforming growth factor (TGF)-beta.	Atorvastatin	0-12	interleukin 10	Mus musculus	104-109	
33279615-4	2021	Moreover, atorvastatin reversed microbial composition (characterized by increased abundance of Firmicutes and Lactobacillus and decreased Bacteroidetes abundance), increased fecal butyrate level, promoted intestinal barrier function (elevated protein levels of claudin-1, occludin and mucoprotein 2), as well as regulated intestinal immune function (decreased MCP-1, TNF-alpha and increased IL-10).	Atorvastatin	10-22	interleukin 10	Mus musculus	391-396